help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunaif, A.
Right arrow Articles by Dobrjansky, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunaif, A.
Right arrow Articles by Dobrjansky, A.

Journal of Clinical Endocrinology & Metabolism, Vol 65, 499-507, Copyright © 1987 by Endocrine Society

ARTICLES

Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia

A Dunaif, M Graf, J Mandeli, V Laumas and A Dobrjansky

This study examined the prevalence of both basal and glucose-stimulated hyperinsulinemia and acanthosis nigricans (AN) as well as the relationship between insulin and androgen levels in hyperandrogenic women. Sixty-two women who had an elevation of 1 or more plasma androgen levels were studied. The results in these women, grouped for analysis on the basis of obesity and ovulatory status, were compared to those in 36 control women of similar ages and weights. The anovulatory hyperandrogenic women had the clinical and biochemical features of the polycystic ovary syndrome (PCO). Oral glucose tolerance tests were performed with measurement of glucose, insulin, sex hormone-binding globulin (SHBG), and total and non-SHBG-bound sex steroid levels. AN was present in 29% of the hyperandrogenic women, the majority of them obese. Fifty percent of obese PCO women had AN, but they did not otherwise differ from PCO women lacking this dermatological change. Only women with PCO had significant hyperinsulinemia independent of obesity, and obese PCO women with AN had the highest serum insulin levels. Plasma glucose values during the oral glucose tolerance test were significantly increased in obese PCO women independent of the presence of AN, and 20% of these women had frank impairment of glucose tolerance. Ovulatory hyperandrogenic women had normal insulin levels and glucose tolerance. Obese and nonobese women had different relationships between sex steroid and insulin levels; obese women had significant correlations between insulin and non-SHBG testosterone levels (r = 0.30; P less than 0.05), whereas nonobese women had significant correlations between insulin and FSH (r = 0.40; P less than 0.01), dehydroepiandrosterone sulfate (r = 0.33; P less than 0.05), and SHBG (r = 0.37; P less than 0.05) levels, suggesting that the mechanisms underlying the association between sex steroid and insulin levels are complex. These findings suggest that 1) only women with PCO have hyperinsulinemia independent of obesity; hyperinsulinemia is not a feature of hyperandrogenic states in general; 2) AN is a common finding in obese hyperandrogenic women, particularly those with PCO; 3) only obese PCO women are at risk for impairment of glucose tolerance, independent of the presence of AN, suggesting that the negative impact of PCO and obesity on insulin action is additive; and 4) PCO women with AN can be considered as a subgroup of PCO and do not appear to have a distinct endocrine disorder.


This article has been cited by other articles:


Home page
 Hum ReprodHome page
R. Koivunen, A. Pouta, S. Franks, H. Martikainen, U. Sovio, A-L. Hartikainen, M.I. McCarthy, A. Ruokonen, A. Bloigu, M-R. Jarvelin, et al.
Fecundability and spontaneous abortions in women with self-reported oligo-amenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study
Hum. Reprod., June 10, 2008; (2008) den136v1.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
S. Franks, J. Stark, and K. Hardy
Follicle dynamics and anovulation in polycystic ovary syndrome
Hum. Reprod. Update, May 22, 2008; (2008) dmn015v1.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. E. Nestler
Metformin for the Treatment of the Polycystic Ovary Syndrome
N. Engl. J. Med., January 3, 2008; 358(1): 47 - 54.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
P. Vigil, P. Contreras, J. L. Alvarado, A. Godoy, A. M. Salgado, and M. E. Cortes
Evidence of subpopulations with different levels of insulin resistance in women with polycystic ovary syndrome
Hum. Reprod., November 1, 2007; 22(11): 2974 - 2980.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Hu, A. Leonard, A. Seifalian, and P. Hardiman
Vascular dysfunction during pregnancy in women with polycystic ovary syndrome
Hum. Reprod., June 1, 2007; 22(6): 1532 - 1539.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
K. Rautio, J.S. Tapanainen, A. Ruokonen, and L.C. Morin-Papunen
Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study
Hum. Reprod., June 1, 2006; 21(6): 1400 - 1407.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
J. Kwintkiewicz, R. Z. Spaczynski, N. Foyouzi, T. Pehlivan, and A. J. Duleba
Insulin and Oxidative Stress Modulate Proliferation of Rat Ovarian Theca-Interstitial Cells Through Diverse Signal Transduction Pathways
Biol Reprod, June 1, 2006; 74(6): 1034 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Sam, R. S. Legro, P. A. Essah, T. Apridonidze, and A. Dunaif
Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome
PNAS, May 2, 2006; 103(18): 7030 - 7035.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Franks
Diagnosis of Polycystic Ovarian Syndrome: In Defense of the Rotterdam Criteria
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 786 - 789.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Urbanek, A. Woodroffe, K. G. Ewens, E. Diamanti-Kandarakis, R. S. Legro, J. F. Strauss III, A. Dunaif, and R. S. Spielman
Candidate Gene Region for Polycystic Ovary Syndrome on Chromosome 19p13.2
J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6623 - 6629.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
E. Diamanti-Kandarakis and C. Piperi
Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth
Hum. Reprod. Update, November 1, 2005; 11(6): 631 - 643.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
K. Lakhani, A. Leonard, A.M. Seifalian, and P. Hardiman
Microvascular dysfunction in women with polycystic ovary syndrome
Hum. Reprod., November 1, 2005; 20(11): 3219 - 3224.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
I.A.A. Penna, P.R.B. Canella, R.M. Reis, M.F. Silva de Sa, and R.A. Ferriani
Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study
Hum. Reprod., September 1, 2005; 20(9): 2396 - 2401.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Sam, R. S. Legro, R. Bentley-Lewis, and A. Dunaif
Dyslipidemia and Metabolic Syndrome in the Sisters of Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4797 - 4802.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
T. Sir-Petermann, C. Hitchsfeld, M. Maliqueo, E. Codner, B. Echiburu, R. Gazitua, S. Recabarren, and F. Cassorla
Birth weight in offspring of mothers with polycystic ovarian syndrome
Hum. Reprod., August 1, 2005; 20(8): 2122 - 2126.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
D.H. Abbott, D.K. Barnett, C.M. Bruns, and D.A. Dumesic
Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?
Hum. Reprod. Update, July 1, 2005; 11(4): 357 - 374.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. S. Legro, C. L. Gnatuk, A. R. Kunselman, and A. Dunaif
Changes in Glucose Tolerance over Time in Women with Polycystic Ovary Syndrome: A Controlled Study
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3236 - 3242.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
E Diamanti-Kandarakis, K Alexandraki, A Protogerou, C Piperi, C Papamichael, A Aessopos, J Lekakis, and M Mavrikakis
Metformin administration improves endothelial function in women with polycystic ovary syndrome
Eur. J. Endocrinol., May 1, 2005; 152(5): 749 - 756.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. S. Legro, P. Chiu, A. R. Kunselman, C. M. Bentley, W. C. Dodson, and A. Dunaif
Polycystic Ovaries Are Common in Women with Hyperandrogenic Chronic Anovulation but Do Not Predict Metabolic or Reproductive Phenotype
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2571 - 2579.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. V. Mehta, K. S. Patel, M. S. Coffler, M. H. Dahan, R. Y. Yoo, J. S. Archer, P. J. Malcom, and R. J. Chang
Luteinizing Hormone Secretion Is Not Influenced by Insulin Infusion in Women with Polycystic Ovary Syndrome Despite Improved Insulin Sensitivity during Pioglitazone Treatment
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2136 - 2141.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. O. Goodarzi, S. Erickson, S. C. Port, R. I. Jennrich, and S. G. Korenman
{beta}-Cell Function: A Key Pathological Determinant in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 310 - 315.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
B. MOZZANEGA, R. MIONI, M. GRANZOTTO, S. CHIARELLI, N. XAMIN, L. ZULIANI, N. SICOLO, D. MARCHESONI, and R. VETTOR
Obesity Reduces the Expression of GLUT4 in the Endometrium of Normoinsulinemic Women Affected by the Polycystic Ovary Syndrome
Ann. N.Y. Acad. Sci., December 1, 2004; 1034(1): 364 - 374.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Mioni, S. Chiarelli, N. Xamin, L. Zuliani, M. Granzotto, B. Mozzanega, P. Maffei, C. Martini, S. Blandamura, N. Sicolo, et al.
Evidence for the Presence of Glucose Transporter 4 in the Endometrium and Its Regulation in Polycystic Ovary Syndrome Patients
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 4089 - 4096.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A.J. Duleba, N. Foyouzi, M. Karaca, T. Pehlivan, J. Kwintkiewicz, and H.R. Behrman
Proliferation of ovarian theca-interstitial cells is modulated by antioxidants and oxidative stress
Hum. Reprod., July 1, 2004; 19(7): 1519 - 1524.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. A. Ganie, M. L. Khurana, M. Eunice, M. Gulati, S. N. Dwivedi, and A. C. Ammini
Comparison of Efficacy of Spironolactone with Metformin in the Management of Polycystic Ovary Syndrome: An Open-Labeled Study
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2756 - 2762.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
R. J. Norman, M. Noakes, R. Wu, M. J. Davies, L. Moran, and J. X. Wang
Improving reproductive performance in overweight/obese women with effective weight management
Hum. Reprod. Update, May 1, 2004; 10(3): 267 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)
Hum. Reprod., January 1, 2004; 19(1): 41 - 47.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
D. S. Guzick
Polycystic Ovary Syndrome
Obstet. Gynecol., January 1, 2004; 103(1): 181 - 193.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Morin-Papunen, K. Rautio, A. Ruokonen, P. Hedberg, M. Puukka, and J. S. Tapanainen
Metformin Reduces Serum C-Reactive Protein Levels in Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4649 - 4654.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
J. L. Sharpless
Polycystic Ovary Syndrome and the Metabolic Syndrome
Clin. Diabetes, October 1, 2003; 21(4): 154 - 161.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. S. Legro
Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association?
Endocr. Rev., June 1, 2003; 24(3): 302 - 312.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Diamanti-Kandarakis, J.-P. Baillargeon, M. J. Iuorno, D. J. Jakubowicz, and J. E. Nestler
A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1927 - 1932.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. Kaaks, A. Lukanova, and M. S. Kurzer
Obesity, Endogenous Hormones, and Endometrial Cancer Risk: A Synthetic Review
Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1531 - 1543.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Cibula, J. Skrha, M. Hill, M. Fanta, L. Haakova, J. VrbIkova, and J. Zivny
Prediction of Insulin Sensitivity in Nonobese Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5821 - 5825.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
L. A. Stadtmauer, B. C. Wong, and S. Oehninger
Should patients with polycystic ovary syndrome be treated with metformin?: Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction
Hum. Reprod., December 1, 2002; 17(12): 3016 - 3026.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Bagis, A. Gokcel, H. B. Zeyneloglu, E. Tarim, E. B. Kilicdag, and B. Haydardedeoglu
The Effects of Short-Term Medroxyprogesterone Acetate and Micronized Progesterone on Glucose Metabolism and Lipid Profiles in Patients with Polycystic Ovary Syndrome: A Prospective Randomized Study
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4536 - 4540.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. E. Silfen, C. H. L. Shackleton, A. M. Manibo, L. S. Levine, D. Sekhar, D. J. McMahon, and S. E. Oberfield
5{alpha}-Reductase and 11{beta}-Hydroxysteroid Dehydrogenase Activity in Prepubertal Hispanic Girls with Premature Adrenarche
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4647 - 4651.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
E. Seli and A. J. Duleba
Should patients with polycystic ovarian syndrome be treated with metformin?
Hum. Reprod., September 1, 2002; 17(9): 2230 - 2236.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
K. Elter, G. Imir, and F. Durmusoglu
Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study
Hum. Reprod., July 1, 2002; 17(7): 1729 - 1737.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. S. Legro, R. Bentley-Lewis, D. Driscoll, S. C. Wang, and A. Dunaif
Insulin Resistance in the Sisters of Women with Polycystic Ovary Syndrome: Association with Hyperandrogenemia Rather Than Menstrual Irregularity
J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2128 - 2133.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Jayagopal, E. S. Kilpatrick, S. Holding, P. E. Jennings, and S. L. Atkin
The Biological Variation of Insulin Resistance in Polycystic Ovarian Syndrome
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1560 - 1562.
[Abstract] [Full Text] [PDF]

Home page
 AAP Grand RoundsHome page
G. D. Comerci
Irregular Menses: A Marker for Risk of Type 2 Diabetes
AAP Grand Rounds, April 1, 2002; 7(4): 41 - 42.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. J. G. Kelly, A. Speirs, G. W. Gould, J. R. Petrie, H. Lyall, and J. M. C. Connell
Altered Vascular Function in Young Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 742 - 746.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
H. Yarali, B. O. Yildiz, A. Demirol, H. B. Zeyneloglu, N. Yigit, O. Bukulmez, and Z. Koray
Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial
Hum. Reprod., February 1, 2002; 17(2): 289 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
D. Cibula, M. Fanta, M. Hill, G. Sindelka, J. Skrha, and J. Zivny
Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin
Hum. Reprod., January 1, 2002; 17(1): 76 - 82.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. G. Solomon, F. B. Hu, A. Dunaif, J. Rich-Edwards, W. C. Willett, D. J. Hunter, G. A. Colditz, F. E. Speizer, and J. E. Manson
Long or Highly Irregular Menstrual Cycles as a Marker for Risk of Type 2 Diabetes Mellitus
JAMA, November 21, 2001; 286(19): 2421 - 2426.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
L. Ciotta, A. E. Calogero, M. Farina, V. De Leo, A. La Marca, and A. Cianci
Clinical, endocrine and metabolic effects of acarbose, an {alpha}-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance
Hum. Reprod., October 1, 2001; 16(10): 2066 - 2072.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
A. J. Duleba, T. Pehlivan, R. Carbone, and R. Z. Spaczynski
Activin Stimulates Proliferation of Rat Ovarian Thecal-Interstitial Cells
Biol Reprod, September 1, 2001; 65(3): 704 - 709.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M. Maliqueo, T. Sir-Petermann, G. Salazar, F. Perez-Bravo, S.E. Recabarren, and L. Wildt
Resumption of ovarian function during lactational amenorrhoea in breastfeeding women with polycystic ovarian syndrome: metabolic aspects
Hum. Reprod., August 1, 2001; 16(8): 1598 - 1602.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
P.M. Spritzer, M. Poy, D. Wiltgen, L.S. Mylius, and E. Capp
Leptin concentrations in hirsute women with polycystic ovary syndrome or idiopathic hirsutism: influence on LH and relationship with hormonal, metabolic, and anthropometric measurements
Hum. Reprod., July 1, 2001; 16(7): 1340 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Colilla, N. J. Cox, and D. A. Ehrmann
Heritability of Insulin Secretion and Insulin Action in Women with Polycystic Ovary Syndrome and Their First Degree Relatives
J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2027 - 2031.
[Abstract] [Full Text]

Home page
 Hum ReprodHome page
D. Cibula, M. Hill, M. Fanta, G. Sindelka, and J. Zivny
Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome?
Hum. Reprod., May 1, 2001; 16(5): 940 - 944.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Morimoto, C. Fernandez-Mejia, G. Romero-Navarro, N. Morales-Peza, and V. DÍaz-Sánchez
Testosterone Effect on Insulin Content, Messenger Ribonucleic Acid Levels, Promoter Activity, and Secretion in the Rat
Endocrinology, April 1, 2001; 142(4): 1442 - 1447.
[Abstract] [Full Text]

Home page
 QJMHome page
V.L. Armstrong, M.I. Wiggam, C.N. Ennis, B. Sheridan, A.I. Traub, A.B. Atkinson, and P.M. Bell
Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate
QJM, January 1, 2001; 94(1): 31 - 37.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. E. Brown, J. P. Toner, J. A. Schnorr, S. C. Williams, W. E. Gibbons, D. de Ziegler, and S. Oehninger
Vaginal misoprostol enhances intrauterine insemination
Hum. Reprod., January 1, 2001; 16(1): 96 - 101.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. Ibáñez, J. DiMartino-Nardi, N. Potau, and P. Saenger
Premature Adrenarche--Normal Variant or Forerunner of Adult Disease?
Endocr. Rev., December 1, 2000; 21(6): 671 - 696.
[Abstract] [Full Text]

Home page
 Hum ReprodHome page
G. Gennarelli, J. Holte, L. Berglund, C. Berne, M. Massobrio, and H. Lithell
Prediction models for insulin resistance in the polycystic ovary syndrome
Hum. Reprod., October 1, 2000; 15(10): 2098 - 2102.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
L. C. Morin-Papunen, I. Vauhkonen, R. M. Koivunen, A. Ruokonen, and J. S. Tapanainen
Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome
Hum. Reprod., June 1, 2000; 15(6): 1266 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
D. Cibula, R. Cifkova, M. Fanta, R. Poledne, J. Zivny, and J. Skibova
Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome
Hum. Reprod., April 1, 2000; 15(4): 785 - 789.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
L. Ciotta, V. De Leo, F. Galvani, A. La Marca, and A. Cianci
Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia
Hum. Reprod., December 1, 1999; 14(12): 2951 - 2958.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.